Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2006 1
2016 1
2018 1
2020 1
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

5 results
Results by year
Filters applied: . Clear all The following terms were not found in PubMed: SB-240683, pascolizuma
Page 1
Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma.
Hart TK, Blackburn MN, Brigham-Burke M, Dede K, Al-Mahdi N, Zia-Amirhosseini P, Cook RM. Hart TK, et al. Clin Exp Immunol. 2002 Oct;130(1):93-100. doi: 10.1046/j.1365-2249.2002.01973.x. Clin Exp Immunol. 2002. PMID: 12296858 Free PMC article.
Affinity studies demonstrated rapid IL-4 binding by pascolizumab with a slow dissociation rate. In vivo pharmacokinetic and chronic safety testing in cynomolgus monkeys demonstrated that pascolizumab was well tolerated, and no adverse clinical responses occurred aft …
Affinity studies demonstrated rapid IL-4 binding by pascolizumab with a slow dissociation rate. In vivo pharmacokinetic and chronic s …
Modulating Interleukins and their Receptors Interactions with Small Chemicals Using In Silico Approach for Asthma.
Majumdar S, Ghosh A, Saha S. Majumdar S, et al. Curr Top Med Chem. 2018;18(13):1123-1134. doi: 10.2174/1568026618666180801092839. Curr Top Med Chem. 2018. PMID: 30068279 Review.
Most of the MAbs including Tracolizumab, Lebrikizumab, Anrukinzumab (Anti IL-13 MAb), and Brodalumab (Anti IL-17 MAb) are in different phases of clinical trials. Pascolizumab (Anti IL-4 MAb), however, has failed. These MAbs are expensive and may render adverse immune respo …
Most of the MAbs including Tracolizumab, Lebrikizumab, Anrukinzumab (Anti IL-13 MAb), and Brodalumab (Anti IL-17 MAb) are in different phase …
A Critical Evaluation of Anti-IL-13 and Anti-IL-4 Strategies in Severe Asthma.
Bagnasco D, Ferrando M, Varricchi G, Passalacqua G, Canonica GW. Bagnasco D, et al. Int Arch Allergy Immunol. 2016;170(2):122-31. doi: 10.1159/000447692. Epub 2016 Aug 3. Int Arch Allergy Immunol. 2016. PMID: 27637004 Free article. Review.
Such studies facilitate better definition of the possible predictive markers of response to a specific treatment (e.g. eosinophils, total IgE, fraction of exhaled nitric oxide and periostin). In parallel, anti-IL-4 strategies have been attempted (pascolizumab, pitakinra an …
Such studies facilitate better definition of the possible predictive markers of response to a specific treatment (e.g. eosinophils, total Ig …
[Current and future approaches for the treatment of inflammatory diseases of inferior respiratory tract].
Guidos Fogelbach GA, Rodríguez Velasco JG, Almeida Arvizu VM. Guidos Fogelbach GA, et al. Rev Alerg Mex. 2006 May-Jun;53(3):94-100. Rev Alerg Mex. 2006. PMID: 16970111 Review. Spanish.
New medicines are being developed with less adverse or secondary effects, and much more selective and specific in the molecules involved in the allergic disease's physiopathology. Among them we find pascolizumab, which inhibits the differentiation made to Th2, as well as t …
New medicines are being developed with less adverse or secondary effects, and much more selective and specific in the molecules involved in …
Targeting IL-4 for the Treatment of Atopic Dermatitis.
Chiricozzi A, Maurelli M, Peris K, Girolomoni G. Chiricozzi A, et al. Immunotargets Ther. 2020 Sep 29;9:151-156. doi: 10.2147/ITT.S260370. eCollection 2020. Immunotargets Ther. 2020. PMID: 33062619 Free PMC article. Review.